DOAC use was associated with a decreased risk of stroke and death compared with warfarin among patients with incident nonvalvular atrial fibrillation (HR 0.90; 95% CI 0.83-0.97).
Cohort (n=34,965)
Do direct oral anticoagulants (DOACs) reduce the composite of stroke and death compared to warfarin in patients with incident nonvalvular atrial fibrillation?
In a real-world Canadian cohort, DOACs were associated with a lower risk of stroke and death compared to warfarin in patients with incident nonvalvular atrial fibrillation.
Hazard Ratio: 0.9 (95% CI 0.83–0.97)
BACKGROUND: Direct oral anticoagulants (DOACs) are noninferior to warfarin for stroke prevention in atrial fibrillation (AF). We aimed to determine the population risk of stroke and death in incident AF, stratified by anticoagulation status and type, and the temporal trends of oral anticoagulation practice in the post-DOAC approval period. METHODS AND RESULTS: We conducted a population-based cohort study of incident nonvalvular AF cases using administrative health data in Alberta, Canada. We used Cox proportional hazards modeling with anticoagulation status as a time-varying exposure and adjusted for age (continuous), sex, congestive heart failure, hypertension, diabetes mellitus, prior transient ischemic attack or ischemic stroke, myocardial infarction, peripheral artery disease, and chronic kidney disease. Primary outcome was the composite of stroke and death. Among 34 965 patients with incident AF (56.0% male, median age 73 years), relative to warfarin, DOAC use was associated with decreased risk of all stroke and death (hazard ratio: 0.90; 95% confidence interval, 0.83-0.97) and decreased hemorrhagic stroke (hazard ratio: 0.60; 95% confidence interval, 0.40-0.91]) but a similar risk of ischemic stroke (hazard ratio: 1.12; 95% confidence interval, 0.94-1.34]). During this time period, DOAC use increased rapidly, surpassing warfarin, but the total oral anticoagulation use in the population remained stable, even in the subgroup with the highest thromboembolic risk. CONCLUSIONS: In a real-world population-based study of patients with incident AF, anticoagulation with DOACs was associated with decreased risk of stroke and death compared with warfarin. Despite a rapid uptake of DOACs in clinical practice, the total proportion of AF patients on anticoagulation has remained stable, even in high-risk patients.
Yu et al. (Sun,) conducted a cohort in Incident nonvalvular atrial fibrillation (n=34,965). Direct oral anticoagulants (DOACs) vs. Warfarin was evaluated on Composite of stroke and death (HR 0.90, 95% CI 0.83-0.97). DOAC use was associated with a decreased risk of stroke and death compared with warfarin among patients with incident nonvalvular atrial fibrillation (HR 0.90; 95% CI 0.83-0.97).